ARID1A and bladder transitional cell carcinoma: ARID1A-inactivating mutations are observed in 20% of BLCA tumors, affecting essential signaling pathways such as PI3K/AKT signaling, which renders the protein a potential target in synergistic therapeutic approaches for the management of BLCA patients [57].